Similar articles

• [Changes in trimethoprim levels and its pharmacokinetic parameters in children with chronic renal failure treated with biseptol. I].

  Sieniawska M, Białasik D, Wróblewska-Kałuzewska M, Korniszewska J, Wierzbowska-Lange B, Karczeńska J, Wierzba K. Sieniawska M, et al. Pediatr Pol. 1984 Mar;59(3):177-87. Pediatr Pol. 1984. PMID: 6610853 Polish. No abstract available.
• Therapeutic progress: trimethoprim-sulfamethoxazole.

  Ruiz López R, Saavedra S, Ramírez-Ronda CH. Ruiz López R, et al. Bol Asoc Med P R. 1984 Jul;76(7):309-13. Bol Asoc Med P R. 1984. PMID: 6332635 No abstract available.
• [Role of the skin in the distribution of co-trimoxazole components].

  Nowak A, Kadyków M, Klimowicz A. Nowak A, et al. Pol Tyg Lek. 1983 Mar 28;38(13):393-6. Pol Tyg Lek. 1983. PMID: 6605526 Polish. No abstract available.
• [Co-trimoxazole chemoprophylaxis in immunocompromised patients: analysis of the literature].

  Gava R, Carli M. Gava R, et al. G Clin Med. 1989 Jan;70(1):37-9, 42-6. G Clin Med. 1989. PMID: 2668092 Review. Italian. No abstract available.
• Trimethoprim-sulfamethoxazole: an assessment of more than 12 years of use.

  Salter AJ. Salter AJ. Rev Infect Dis. 1982 Mar-Apr;4(2):196-236. doi: 10.1093/clinids/4.2.196. Rev Infect Dis. 1982. PMID: 7051224 Review. No abstract available.